FDA Grants Breakthrough Designation to LOXO-292 for Thyroid Cancer Subtype
The FDA has granted a breakthrough therapy designation to LOXO-292 for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options.
Progress and Opportunities in HER2+ Breast Cancer Treatment
Oncologist Kelly McCann, MD, PhD, reviews the vast improvements in the treatment landscape for patients with HER2-positive breast cancer, as well as the work that lies ahead.
What the Frontline Osimertinib Approval Means for Treatment of EGFR+ NSCLC
Helena A. Yu, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explains the implications of the approval of osimertinib as the frontline standard of care for patients with EGFR-mutant non–small cell lung cancer.
New Treatments for Lesser-Known Targets in NSCLC are Emerging
Therapeutic strategies for treating less-common molecular targets found in non–small cell lung cancer (NSCLC), such as ROS1, NTRK, MET, and HER2, are under development.
CDK 4/6 Inhibitors Revolutionized Breast Cancer Treatment
Three CDK 4/6 inhibitors—palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio)— are game-changers in the field of breast cancer, explained Richard S. Finn, MD.
New Discoveries in AML Treatments Bring Hope
Expert Jeffrey Lancet, MD, discusses the emerging agents in treating acute myeloid leukemia (AML) and challenges that still exist for improving patient outcome.
Patients in Treatment for Melanoma Require Close Monitoring
Even if a patient is being treated for melanoma, they should still be getting examined for new primary melanomas, as well as skin-related adverse events.
Improving Uptake of Low-Dose CT Screening for Lung Cancer in High-Risk Patients
Patients with lung cancer who received low-dose CT scans had a 15% to 20% lower risk of death from their disease versus those who had standard chest X-rays, which has led to screening guidelines.
Patient-Centered and Family-Oriented Palliative Care Improves QOL in Lung Cancer
Inaccurate ideas of palliative care can negative effect the outcomes for patients with lung cancer.
Adolescents and Young Adults With Lymphoma Have Unique Medical, Psychosocial Needs
There are specific challenges when treating AYA patients with Hodgkin lymphoma.
Why Genetic Testing Is So Important in Ovarian Cancer
For BRCA1/2 and other genes, it is important that practitioners begin testing for heriditary genes for ovarian cancers.
New Agents, Combinations Showing Durable Benefit in Triple-Negative Breast Cancer
Expert Joyce O'Shaughnessy discusses current topics in breast cancer, particular the advances and future for triple-negative breast cancer (TNBC).
Radium-223 Continues to Benefit Patients With Castration Resistant Prostate Cancer
Expert Michael Morris, MD, discusses the current and future role of radium-223 dichloride in treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
Stem Cell Transplant Continues as Main Curative Therapy for Myeloma
Stem cell transplant remains to be a curative and reliable strategy for multiple myeloma and other hematologic malignancies.
Deciding Which Patients May Benefit from Adding Frontline Chemo to ADT for Metastatic Prostate Cancer
Tanya Dorff, MD, explains the developments of chemotherapy in firstline treatment for hormone-sensitive metastatic prostate cancer as well as personalized treatment in this population.
SPINET Trial Could Alter Practice for Patients With Lung NETs
Somatostatin analog lanreotide (Somatuline Depot) is being considered for patients with lung neuroendocrine tumors (NETs) in a potentially practice-changing clinical trial.
ADT Associated with Psychological Effects in Patients with Prostate Cancer
Patients undergoing Androgen-deprivation therapy (ADT) for prostate cancer may be at risk of significant psychological effects.
New Margin Width Guideline for DCIS Aims to Improve Surgical Decision Making
New practice guideline now recommends a 2-mm margin width as the standard for patients with DCIS undergoing breast-conserving surgery.
Sarcoma Awareness Spotlight: Why Younger Patients Need More Support
Despite some advances in treatment options for patients with sarcomas, researchers are still actively seeking to improve outcomes for pediatric, adolescent and young adult patients, a group particularly impacted by this diagnosis.
Shining a Light on Life With Lymphoma
For Average Women, Mammograms Should Start at Age 50, Recommends USPSTF
Using an individualized approach to decide whether asymptomatic women under age 50 should have mammograms is at the center of the final screening guidelines published by the US Preventive Services Task Force (USPSTF), but the group
Hormone Therapy May Boost Survival in Ovarian Cancer
For patients with epithelial ovarian cancer, adjuvant hormone therapy (AHT) proved to be safe and reduced the risk of death by 37%, according to findings of a 24-year study recently published in the Journal of Clinical Oncology.
Shaping Survivorship Care Plans for the Future
With today's approximately 14.5 million cancer survivors-a number projected to reach nearly 18 million in 2024-new survivorship models of care are needed.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512